Search Our Scientific Publications & Authors

Metabolomics 2021 03 3;17(3):29. Epub 2021 Mar 3.

Centre for Analytical Bioscience, Advanced Materials and Healthcare Technologies Division, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK.

Introduction: Osteoarthritis (OA) is a common cause of disability in older people, but its aetiology is not yet fully understood. Biomarkers of OA from metabolomics studies have shown potential use in understanding the progression and pathophysiology of OA.

Objectives: To investigate possible surrogate biomarkers of knee OA in urine using metabolomics to contribute towards a better understanding of OA progression and possible targeted treatment. Read More

Rheumatology (Oxford) 2021 Jan 28. Epub 2021 Jan 28.

Academic Rheumatology, Division of Rheumatology, Orthopaedics and Dermatology, University of Nottingham, UK.

Objective: To determine the burden of comorbidities in osteoarthritis (OA) and their temporal relationships in the UK.

Methods: The Clinical Practice Research Datalink (CPRD) GOLD was used to identify people with incident OA and age, gender and practice matched non-OA controls from UK primary care. Controls were assigned the same index date as matched cases (date of OA diagnosis). Read More

J Orthop Res 2020 Nov 25. Epub 2020 Nov 25.

Medical Device Research Institute, College of Science and Engineering, Flinders University, Adelaide, South Australia, Australia.

This preliminary study quantified tibia cartilage thickness (Cart.Th), subchondral bone plate thickness (SBPl.Th) and subchondral trabecular bone (STB) microarchitecture in subjects with varus- or valgus- malaligned knees diagnosed with end-stage knee osteoarthritis (OA) and compared them to controls (non-OA). Read More

Int J Mol Sci 2020 08 21;21(17). Epub 2020 Aug 21.

Rheumatology Unit, Department of Medicine-DIMED, University-Hospital of Padova, Via Giustiniani, 2, 35128 Padova, Italy.

Osteoarthritis (OA) is one of the most common joint disorders. Evidence suggests that the infrapatellar fat pad (IFP) is directly involved in OA pathology. However, a comparison between OA versus non-OA IFP is still missing. Read More

Biomedicines 2020 Aug 11;8(8). Epub 2020 Aug 11.

Experimental Plastic Surgery, Clinic for Plastic, Reconstructive and Hand Surgery, Klinikum Rechts der Isar, Technische Universität München, D-81675 Munich, Germany.

Patients suffering from tissue ischemia, who would greatly benefit from angiogenesis-promoting therapies such as hypoxia preconditioned blood-derived secretomes commonly receive oral anticoagulation (OA) and/or have diabetes mellitus (DM). In this study, we investigated the effect of OA administration on the in vitro angiogenic potential of hypoxia preconditioned plasma (HPP) and serum (HPS), prepared from nondiabetic/diabetic subjects who did not receive OA ( = 5) or were treated with acetylsalicylic acid (ASA, = 8), ASA + clopidogrel ( = 10), or nonvitamin K antagonist oral anticoagulants ( = 7) for longer than six months. The effect of DM was differentially assessed by comparing HPP/HPS obtained from nondiabetic ( = 8) and diabetic ( = 16) subjects who had not received OA in the past six months. Read More